Keyword: Kadcyla

Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.

Roche has sealed a deal to provide Gazyvaro to U.K. patients through the revamped Cancer Drugs Fund.

After years of back and forth, U.K. drug cost watchdog NICE said today it has deemed Roche's breast cancer drug Kadcyla as cost effective.

Swiss cancer major Roche has delivered a solid set of financials this morning as the drugmaker looks toward a strong 2016 with a host of new approvals on the horizon.

@FiercePharma: Trending on our website (still): If pharma reps can't get in doctors' front doors, try alternate routes. Story | Follow @FiercePharma @EricPFierce: U.K. tosses lean, but...